Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 Inhibitor

(MedPage Today) -- ORLANDO--More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of treatment with an investigational dual-target small-molecule inhibitor, according to a study...